Decision/Conclude agreement
Proposed
方達控股目標業務出售予Charles River Laboratories
方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories,作為其私有化及業務分拆的一部分,讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。
Trajectories
Sign-in readers can mine up to three arcs for this record.
Actors and targets
Source
生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元
Not established
- Announcement date
- Expected closing date
- Transaction currency of payment
- Financing structure
Extracted detail
Related decisions
Same kind only, ranked by embedding similarity to this record.